CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)-Results of an initial safety cohort
Hall, M. Allan, K. Michael, A. Clamp, Andrew R Glasspool, R. Nicum, S. Lord, R. Banerjee, S. N. Roche, J. Stobo, J.
Hall, M.
Allan, K.
Michael, A.
Clamp, Andrew R
Glasspool, R.
Nicum, S.
Lord, R.
Banerjee, S. N.
Roche, J.
Stobo, J.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Hall M, Allan K, Michael A, Clamp AR, Glasspool R, Nicum S, et al. CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)-Results of an initial safety cohort. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301633.